Arcutis Biotherapeutics, Inc.
ARQT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,406 | $1,780 | $1,971 | $1,685 |
| - Cash | $47 | $73 | $53 | $71 |
| + Debt | $6 | $110 | $111 | $111 |
| Enterprise Value | $2,365 | $1,818 | $2,029 | $1,724 |
| Revenue | $99 | $82 | $66 | $71 |
| % Growth | 21.7% | 23.8% | -7.7% | – |
| Gross Profit | $91 | $74 | $57 | $64 |
| % Margin | 91.2% | 90.8% | 86.6% | 90.3% |
| EBITDA | $11 | -$12 | -$19 | -$4 |
| % Margin | 11.2% | -14.7% | -28.3% | -6.2% |
| Net Income | $7 | -$16 | -$25 | -$11 |
| % Margin | 7.5% | -19.5% | -38.1% | -15.1% |
| EPS Diluted | 0.06 | -0.13 | -0.2 | -0.089 |
| % Growth | 146.2% | 35% | -124.2% | – |
| Operating Cash Flow | -$2 | $0 | -$30 | -$1 |
| Capital Expenditures | $0 | -$0 | -$1 | -$5 |
| Free Cash Flow | -$2 | $0 | -$31 | -$6 |